» Articles » PMID: 23009227

The Effects of Varying Acidity on Helicobacter Pylori Growth and the Bactericidal Efficacy of Ampicillin

Overview
Date 2012 Sep 27
PMID 23009227
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Penicillins inhibit cell wall synthesis; therefore, Helicobacter pylori must be dividing for this class of antibiotics to be effective in eradication therapy. Identifying growth responses to varying medium pH may allow design of more effective treatment regimens.

Aim: To determine the effects of acidity on bacterial growth and the bactericidal efficacy of ampicillin.

Methods: H. pylori were incubated in dialysis chambers suspended in 1.5-L of media at various pHs with 5 mM urea, with or without ampicillin, for 4, 8 or 16 h, thus mimicking unbuffered gastric juice. Changes in gene expression, viability and survival were determined.

Results: At pH 3.0, but not at pH 4.5 or 7.4, there was decreased expression of ~400 genes, including many cell envelope biosynthesis, cell division and penicillin-binding protein genes. Ampicillin was bactericidal at pH 4.5 and 7.4, but not at pH 3.0.

Conclusions: Ampicillin is bactericidal at pH 4.5 and 7.4, but not at pH 3.0, due to decreased expression of cell envelope and division genes with loss of cell division at pH 3.0. Therefore, at pH 3.0, the likely pH at the gastric surface, the bacteria are nondividing and persist with ampicillin treatment. A more effective inhibitor of acid secretion that maintains gastric pH near neutrality for 24 h/day should enhance the efficacy of amoxicillin, improving triple therapy and likely even allowing dual amoxicillin-based therapy for H. pylori eradication.

Citing Articles

In Vitro Susceptibility and Synergistic Effect of Bismuth Against .

Woo J, Bang C, Lee J, Ahn J, Kim J, Jung H Antibiotics (Basel). 2024; 13(11).

PMID: 39596699 PMC: 11591412. DOI: 10.3390/antibiotics13111004.


GERD: Latest update on acid-suppressant drugs.

Al-Frejat Z, Martini N, Esper A, Al-Frejat D, Younes S, Hanna M Curr Res Pharmacol Drug Discov. 2024; 7:100198.

PMID: 39282236 PMC: 11393603. DOI: 10.1016/j.crphar.2024.100198.


: High dose amoxicillin does not improve primary or secondary eradication rates in an Irish cohort.

Costigan C, OSullivan A, OConnell J, Sengupta S, Butler T, Molloy S World J Clin Cases. 2024; 12(16):2773-2779.

PMID: 38899284 PMC: 11185322. DOI: 10.12998/wjcc.v12.i16.2773.


Vonoprazan: A Review in Helicobacter pylori Infection.

Shirley M Drugs. 2024; 84(3):319-327.

PMID: 38388872 PMC: 11090951. DOI: 10.1007/s40265-023-01991-5.


Evolving Concepts in Helicobacter pylori Management.

Moss S, Shah S, Tan M, El-Serag H Gastroenterology. 2023; 166(2):267-283.

PMID: 37806461 PMC: 10843279. DOI: 10.1053/j.gastro.2023.09.047.


References
1.
Sachs G, Scott D . Helicobacter pylori: Eradication or Preservation. F1000 Med Rep. 2012; 4:7. PMC: 3318258. DOI: 10.3410/M4-7. View

2.
Dent J, Kahrilas P, Hatlebakk J, Vakil N, Denison H, Franzen S . A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease. Am J Gastroenterol. 2008; 103(1):20-6. DOI: 10.1111/j.1572-0241.2007.01544.x. View

3.
Tomb J, White O, Kerlavage A, Clayton R, Sutton G, Fleischmann R . The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature. 1997; 388(6642):539-47. DOI: 10.1038/41483. View

4.
Blaser M . Helicobacter pylori and esophageal disease: wake-up call?. Gastroenterology. 2010; 139(6):1819-22. PMC: 2997189. DOI: 10.1053/j.gastro.2010.10.037. View

5.
Blaser M . Helicobacter pylori: its role in disease. Clin Infect Dis. 1992; 15(3):386-91. DOI: 10.1093/clind/15.3.386. View